Biogen Aktie - 1BIIB

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

103,00

Gebot

103,00

Fragen

105,80

Volumen

103,00 Tagesbereich 103,00

103,00 52-Wochen-Bereich 220,70

Marktkapitalisierung

15,077B

Handelsende

104,75

Handelsbeginn

103,00

Letzte Trade

103

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

146.374.937

Dividendenrendite

Kurs-Gewinn-Verhältnis

10,78

Gewinn pro Aktie (EPS)

11,15

Erlöse

9,68B

Nettogewinn

1,63B

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.biogen.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the Italienische Börse with ticker 1BIIB. The last closing price for Biogen was 104,75 €. Over the last year, Biogen shares have traded in a share price range of 103,00 € to 220,70 €.

Biogen currently has 146.374.937 shares in issue. The market capitalisation of Biogen is 15,33 € billion. Biogen has a price to earnings ratio (PE ratio) of 10.78.

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union In the...

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease CAMBRIDGE...

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square Biogen signs lease for Kendall Common as part of...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Global...

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare...

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.5	-0.48309178744	103.5	107.35	103	59	104.36564626	DE
4	-23.5	-18.5770750988	126.5	126.5	103	37	108.63865385	DE
12	-35.8	-25.7925072046	138.8	145.05	103	53	128.47270948	DE
26	-69.2	-40.1858304297	172.2	173.4	103	54	138.20251628	DE
52	-93.55	-47.5960315441	196.55	220.7	103	47	153.77366588	DE
156	-112.6	-52.2263450835	215.6	244.6	103	43	162.74406319	DE
260	-112.6	-52.2263450835	215.6	244.6	103	43	162.74406319	DE

1BIIB - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is 103,00 €

How many Biogen shares are in issue?

Biogen has 146.374.937 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is EUR 15,33B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of 103,00 € to 220,70 € during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 10,78

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 1,82

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9,68B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1,63B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WLS26Lemon Sistemi SpA	0,0697 € (16,17%)	38,86k
EPHEPH SpA	0,0756 € (12,50%)	14,36k
WMGSMagis SpA	3,72 € (12,39%)	200
MAIREMaire SpA	9,45 € (11,97%)	3,11M
DIBDigital Bros Spa	11,40 € (11,11%)	82k
WFUMFranchi Umberto Marmi SpA	0,1499 € (-26,30%)	1.000
WSOS26Sostravelcom SpA	0,03 € (-18,70%)	112,3k
BESBestbe Holding	0,188 € (-14,51%)	249,29k
WHIK26Haiki Spa	0,0496 € (-12,98%)	62,8k
1AAgilent Technologies Inc	84,20 € (-9,91%)	1
TITTelecom Italia SpA	0,3482 € (2,02%)	255,08M
ISPIntesa Sanpaolo Spa	4,7665 € (1,58%)	64M
SPMSaipem Spa	2,048 € (0,10%)	29,98M
STLAMStellantis NV	8,296 € (0,91%)	28,36M
FDAFidia	0,0038 € (-7,32%)	28,28M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Biogen Inc (1BIIB) Börsenkurse

Biogen Inc (1BIIB)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Biogen Inc

1BIIB Neueste Nachrichten

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

1BIIB - Frequently Asked Questions (FAQ)

Beweger

1BIIB Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen